Bain Capital Life Sciences Opportunities IV, L.P. has filed a Schedule 13G revealing its acquisition of a 9.99% stake in ADC Therapeutics SA. This filing, dated October 29, 2026, is significant as it underscores Bain's ongoing investment strategy in the life sciences sector, particularly in pharmaceutical preparations.

ADC Therapeutics, based in Switzerland, specializes in developing antibody-drug conjugates for cancer treatment. The company's focus on innovative therapies aligns with Bain Capital's investment philosophy, which seeks to capitalize on advancements in healthcare.

According to the filing, Bain Capital Life Sciences Opportunities IV, L.P. holds 14,825,625 common shares of ADC Therapeutics, which includes 7,000,000 shares and pre-funded warrants to purchase up to 22,703,927 additional shares. However, Bain is restricted from exercising these warrants if it would exceed the 9.99% ownership threshold.

"The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer," the filing states.

This investment may impact ADC Therapeutics' strategic direction and partnerships, as Bain Capital's involvement could bring additional resources and expertise to the company. The pharmaceutical industry, particularly in the realm of cancer treatments, is highly competitive, and Bain's stake may alter how ADC Therapeutics positions itself against rivals.

Moving forward, it remains to be seen how this investment will influence ADC Therapeutics' operations and whether Bain Capital will seek to increase its stake in the company. The filing does not indicate any immediate plans for further action.